0001607062-22-000550.txt : 20220822 0001607062-22-000550.hdr.sgml : 20220822 20220822163249 ACCESSION NUMBER: 0001607062-22-000550 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220822 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220822 DATE AS OF CHANGE: 20220822 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nutex Health, Inc. CENTRAL INDEX KEY: 0001479681 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 113363609 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41346 FILM NUMBER: 221184139 BUSINESS ADDRESS: STREET 1: 2455 EAST SUNRISE BLVD. STREET 2: SUITE 1204 CITY: FORT LAUDERDALE STATE: FL ZIP: 33304 BUSINESS PHONE: (954) 449-4703 MAIL ADDRESS: STREET 1: 2455 EAST SUNRISE BLVD. STREET 2: SUITE 1204 CITY: FORT LAUDERDALE STATE: FL ZIP: 33304 FORMER COMPANY: FORMER CONFORMED NAME: Clinigence Holdings, Inc. DATE OF NAME CHANGE: 20191113 FORMER COMPANY: FORMER CONFORMED NAME: iGambit, Inc. DATE OF NAME CHANGE: 20091230 8-K 1 nutx082222form8k.htm 8-K
0001479681 false 0001479681 2022-08-22 2022-08-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): August 22, 2022

 

NUTEX HEALTH INC.

(Exact name of registrant as specified in its charter)

 

Delaware 000-53862 11-3363609
(State or Other Jurisdiction
of Incorporation)		 (Commission File Number) (I.R.S. Employer
Identification Number)

‎

6030 S. Rice Ave, Suite C, Houston, Texas 77081

(Address of principal executive offices) (zip code)

 

‎(713) 660-0557‎

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐   Precommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐   Precommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbols(s) Name of each exchange on which registered
Common Stock, $0.001 par value  NUTX

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 1 

 

Item 2.02.‎ Results of Operations and Financial Condition

 

On August 22, 2022, Nutex Health Inc. (the “Company”) announced its financial and operating results for the quarter ending June 30, 2022. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.   Description of Exhibit
99.1   Press Release dated August 22, 2022.
104   Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

 

THE INFORMATION CONTAINED IN ITEM 2.02 OF THIS CURRENT REPORT, INCLUDING EXHIBIT 99.1 ATTACHED HERETO, SHALL NOT BE DEEMED “FILED” FOR THE PURPOSES OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, NOR SHALL IT BE DEEMED INCORPORATED BY REFERENCE INTO ANY REGISTRATION STATEMENT OR OTHER FILING PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, EXCEPT AS OTHERWISE EXPRESSLY STATED IN SUCH FILING.

 2 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 22, 2022

Nutex Health Inc.

By: /s/ Jon C. Bates

Jon C. Bates

Chief Financial Officer

 3 

 

 EX-99.1 2 ex99_1.htm EXHIBIT 99.1

NUTEX HEALTH reports secONd quarter 2022 financial results

•EBITDA of $5.4 million for the second quarter of 2022
•adjusted ebitda of $9.4 million for the second quarter of 2022
•NET loss of $19.4 MILLION FOR THE SECOND QUARTER OF 2022
•EBITDA of $29.7 million for the six months ended june 30, 2022
•adjusted ebitda of $33.6 million for the six months ended june 30, 2022
•NET INCOME OF $2.1 MILLION FOR THE SIX MONTHS ENDED JUNE 30, 2022
•Company reiterates that it expects to open 20 NEW facilities by the end of 2024

 

HOUSTON, TX − (PRNewswire) – AUGUST 22, 2022 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks, today announced fiscal year 2022 2nd Quarter financial results for the three months ended June 30, 2022 and the filing of its current report on Form 10-Q for the period ended June 30, 2022 (“10-Q”) with the Securities and Exchange Commission.

Financial Highlights for the Three Months Ended June 30, 2022 (Unaudited):

•Net revenue of $58.0 million.
•Net loss attributable to Nutex Health of $19.4 million. In Q2, the Company recognized a one-time non-cash charge of $18.4 million, net to income tax expense during the three months ended June 30, 2022 for the change in tax status of Nutex Health Holdco LLC and release of acquired valuation allowance of Clinigence. Additionally, the Company recognized one-time acquisition expenses of $3.9 million related to the merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc. Please read “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 10-Q.
•EBITDA of $5.4 million.
•Adjusted EBITDA of $9.4 million.
•As of June 30, 2022, the Company had total assets of $871.8 million, including cash and cash equivalents of $47.6 million.

Financial Highlights for the Six Months Ended June 30, 2022 (Unaudited):

•Net revenue of $137.2 million.
•Net income attributable to Nutex Health of $2.1 million.
•EBITDA of $29.7 million.
•Adjusted EBITDA of $33.6 million.

Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.

Notes to the Financial Highlights for the Three Months Ended June 30, 2022:

•Clinigence Holdings, Inc. and Nutex Health Holdco LLC completed their merger on April 1, 2022. Therefore, the Second Quarter 2022 financial results reflect the consolidated financial results of post-merger Clinigence Holdings, Inc. and Nutex Health Holdco LLC.
•The Company recognized a one-time non-cash charge of $18.4 million, net to income tax expense during the three months ended June 30, 2022 for the change in tax status of Nutex Health Holdco LLC and release of acquired valuation allowance for Clinigence. Prior to the merger with Clinigence, Nutex Health Holdco LLC and the Nutex Subsidiaries were pass-through entities treated as partnerships for U.S. federal income tax purposes. No provision for federal income taxes was provided for these periods as federal taxes were obligations of these companies’ members. After the merger, Nutex Health Holdco LLC became a wholly-owned subsidiary of Clinigence and will be included in its future consolidated corporate tax filings.
•The Company anticipates opening 20 new facilities by the end of 2024. These facilities are either under construction or in advanced planning stages. Three are expected to open in late 2022, with another 17 expected to open in 2023 and 2024. There can be no assurance that these new facilities will open in the anticipated timeframes or that they will open at all.

“In the second quarter, our management team focused on integrating our two companies post-merger,” stated Jon Bates, Chief Financial Officer of Nutex Health. “We believe this integration has now been substantially completed.”

“We are very proud of the hard work of our physicians, nurses, hospital staff and corporate staff to get to this stage. We continue our efforts to grow the Company while providing the best patient care possible. This philosophy dictates all of our decision making as an organization,” stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health. “We are also excited about our pipeline of new facilities which are either under construction or in advanced planning stages throughout the country.”

“The Company has formed two new independent practice associations (IPAs), one in Houston and one in South Florida. We are actively working on contracting with primary care physicians as well as specialists. Once this phase is completed, the Company expects to contract with health insurance plans and start enrolling patients in 2023,” stated Warren Hosseinion, M.D., President of Nutex Health. “We believe that our unique integrated model which combines our cloud-based data analytics platform, micro hospitals and IPAs will create long-term value for our shareholders.”

For more details on the Company’s Second Quarter 2022 financial results, please refer to our Quarterly Report on Form 10-Q filed with the U.S. Securities & Exchange Commission and accessible at www.sec.gov.

 1 

 

 

NUTEX HEALTH INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

 

             
    June 30, 2022   December 31, 2021
Assets            
Current assets:            
Cash and cash equivalents   $  47,600,621   $  36,118,284
Accounts receivable      94,653,853      112,766,317
Accounts receivable - related parties      1,391,049      1,993,117
Inventories      2,907,182      2,814,178
Prepaid expenses and other current assets      2,427,849      323,283
Total current assets      148,980,554      154,015,179
Property and equipment, net      67,822,682      151,912,500
Operating right-of-use assets      23,686,253      21,829,552
Financing right-of-use assets      183,542,400      64,614,781
Intangible assets, net      21,964,230      682,649
Goodwill      425,355,837      1,139,297
Other assets      441,304      456,085
             
Total assets   $  871,793,260   $  394,650,043
             
Liabilities and Equity            
Current liabilities:            
Accounts payable   $  19,954,714   $  13,582,664
Accounts payable - related parties      3,614,326      4,070,438
Lines of credit      2,592,714      72,055
Current portion of long-term debt      7,735,760      10,158,932
Operating lease liabilities, current portion      1,789,871      1,489,997
Financing lease liabilities, current portion      3,592,382      1,452,447
Accrued expenses and other current liabilities      17,191,260      6,864,426
Total current liabilities      56,471,027      37,690,959
Long-term debt, net      16,305,258      78,821,985
Operating lease liabilities, net      22,616,233      20,820,588
Financing lease liabilities, net      192,516,749      65,735,501
Deferred tax liabilities      17,469,750      -
Total liabilities      305,379,017      203,069,033
             
Commitments and contingencies            
             
Equity:            
Common stock, $0.001 par value; 900,000,000 shares authorized; 648,918,458 and 592,791,712 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively      648,918      592,792
Additional paid-in capital      467,402,221      11,742,891
Retained earnings      57,638,688      102,315,623
Nutex Health Inc. equity      525,689,827      114,651,306
Noncontrolling interests      40,724,416      76,929,704
Total equity      566,414,243      191,581,010
             
Total liabilities and equity   $  871,793,260   $  394,650,043

 2 

 

NUTEX HEALTH INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

             
   Three months ended June 30  Six months ended June 30
   2022  2021  2022  2021
Revenue:                    
Hospital division  $51,604,679   $62,814,672   $130,731,921   $150,157,914 
Population health management division   6,443,254    —      6,443,254    —   
Total revenue   58,047,933    62,814,672    137,175,175    150,157,914 
                     
Operating costs and expenses:                    
Payroll   24,045,279    18,261,313    48,502,680    36,026,695 
Contract services   13,478,349    4,235,963    18,883,944    9,036,276 
Medical supplies   2,581,552    2,572,970    6,841,031    4,972,662 
Insurance expense   1,551,696    1,971,574    3,927,679    3,619,305 
Depreciation and amortization   3,132,485    2,223,461    5,529,346    4,001,640 
Other   8,266,046    4,412,059    14,099,991    8,714,161 
Total operating costs and expenses   53,055,407    33,677,340    97,784,671    66,370,739 
                     
Gross profit   4,992,526    29,137,332    39,390,504    83,787,175 
                     
Corporate cost:                    
Acquisition costs   3,885,666    —      3,885,666    —   
General and administrative expenses   2,485,337    1,533,002    7,644,342    3,522,040 
Total corporate cost   6,371,003    1,533,002    11,530,008    3,522,040 
                     
Operating income (loss)   (1,378,477)   27,604,330    27,860,496    80,265,135 
                     
Interest expense   3,849,629    1,504,933    5,705,603    2,991,090 
Other expense (income)   (1,403,222)   (4,060,149)   977,323    (3,921,356)
Income (loss) before taxes   (3,824,884)   30,159,546    21,177,570    81,195,401 
                     
Income tax expense   19,653,286    481,501    19,829,609    638,354 
                     
Net income (loss)   (23,478,170)   29,678,045    1,347,961    80,557,047 
                     
Less: net income (loss) attributable to noncontrolling interests   (4,082,418)   2,618,644    (786,589)   15,735,510 
                     
Net income (loss) attributable to Nutex Health Inc.  $(19,395,752)  $27,059,401   $2,134,550   $64,821,537 
                     
Earnings (loss) per common share                    
Basic  $(0.03)  $0.05   $0.00   $0.11 
Diluted  $(0.03)  $0.05   $0.00   $0.11 
Weighted average shares outstanding                    
Basic   646,370,173    592,791,712    619,728,949    592,791,712 
Diluted   658,991,192    592,791,712    626,992,817    592,791,712 

 

 3 

 

 

NUTEX HEALTH INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

       
   Six months ended June 30
   2022  2021
Cash flows from operating activities:          
Net income  $1,347,961   $80,557,047 
Adjustment to reconcile net income to net cash from operating activities:          
Depreciation and amortization   5,529,346    4,001,640 
Stock-based compensation expense   54,166    —   
Other income - gain on PPP loan forgiveness   —      (4,525,600)
Deferred tax expense   12,013,748    —   
Debt accretion expense   722,536    —   
Non-cash lease expense   109,114    (144,677)
Changes in operating assets and liabilities:          
Accounts receivable   19,745,666    17,338,754 
Accounts receivable - related party   602,068    (150)
Inventories   (93,004)   (2,513)
Prepaid expenses and other current assets   (1,977,182)   (1,022,062)
Accounts payable   6,358,427    4,845,359 
Accounts payable - related party   (630,490)   (793,487)
Accrued expenses and other current liabilities   9,645,922    2,536,291 
Other current assets   (25,219)   (36,120)
Net cash from operating activities   53,403,059    102,754,482 
           
Cash flows from investing activities:          
Acquisitions of property and equipment   (16,621,726)   (21,714,755)
Acquired cash in reverse acquisition with Clinigence   12,716,228    —   
Cash related to deconsolidation of Real Estates Entities   (2,421,212)   —   
Net cash from investing activities   (6,326,710)   (21,714,755)
           
Cash flows from financing activities:          
Proceeds from lines of credit   2,592,714    —   
Proceeds from notes payable   4,865,974    13,966,345 
Repayments of lines of credit   (72,055)   (813,101)
Repayments of notes payable   (4,338,567)   (13,712,534)
Repayments of finance leases   (305,134)   (549,710)
Common stock issued for exercise of warrants   4,119,141    —   
Common stock issued for exercise of options   644,974    —   
Members' contributions   4,731,117    11,033,400 
Members' distributions   (47,832,176)   (78,446,644)
Net cash from financing activities   (35,594,012)   (68,522,244)
           
Net change in cash and cash equivalents   11,482,337    12,517,483 
Cash and cash equivalents - beginning of the period   36,118,284    25,514,275 
Cash and cash equivalents - end of the period   47,600,621    38,031,758 
           
Supplemental disclosures of cash flow information:          
Cash paid for interest  $5,705,603   $2,991,090 
Cash paid for income taxes  $631,400   $316,702 
Non-cash investing and financing activities:          
Acquisition of financing leases  $9,937,104   $452,457 

Non-GAAP Financial Measures

EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA are used as supplemental non-GAAP financial measures by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. We believe EBITDA and Adjusted EBITDA are useful because these measures allow us to more effectively evaluate our operating performance.

We define EBITDA as net income plus net interest expense, depreciation and amortization, and Adjusted EBITDA is further adjusted for stock-based compensation and any acquisition related costs. A reconciliation of net income to EBITDA and Adjusted EBITDA is included below. Neither EBITDA nor Adjusted EBITDA is intended to serve as an alternative to U.S. GAAP measures of performance and may not be comparable to similarly-titled measures presented by other companies.

   Three months ended June 30  Six months ended June 30
   2022  2021  2022  2021
Reconciliation of Net income (loss) attributable to Nutex Health Inc. to Adjusted EBITDA:            
Net income (loss) attributable to Nutex Health Inc.  $(19,395,752)  $27,059,401   $2,134,550   $64,821,537 
Depreciation and amortization   3,132,485    2,223,461    5,529,346    4,001,640 
Interest expense, net   3,849,629    1,504,933    5,705,603    2,991,090 
Income tax expense   19,653,286    481,501    19,829,609    638,354 
Allocation to noncontrolling interests   (1,825,262)   (1,254,592)   (3,521,488)   (2,703,929)
EBITDA   5,414,386    30,014,704    29,677,620    69,748,692 
Stock-based compensation expense   54,166    —      54,166    —   
Acquisition costs   3,885,666    —      3,885,666    —   
Adjusted EBITDA  $9,354,218   $30,014,704   $33,617,452   $69,748,692 

About Nutex Health Inc.

Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. is a physician-led, technology-enabled healthcare services company with approximately 1500 employees nationwide and is partnered with over 800 physicians. The Company has two divisions: a Hospital division and a Population Health Management division.  The Hospital division currently owns and operates 21 facilities in eight different states.  The division implements and operates different innovative health care models, including micro hospitals, specialty hospitals and hospital outpatient departments (HOPDs).  The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organizations (MSOs), we provide management, administrative and other support services to our affiliated hospitals and physician groups.  Our cloud-based proprietary technology platform aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers, allowing us to deliver greater quality care more efficiently. 

Forward-Looking Statements 

Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-Q for the period ended June 30, 2022 under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.

FOR ADDITIONAL INFORMATION:

 

Nutex Health, Inc.

Vivian Sanders – Investor Relations

investors@nutexhealth.com

Jennifer Smith Rodriguez – Media Contact

jsmith@nutexhealth.com

 EX-101.SCH 3 nutx-20220822.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 nutx-20220822_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 nutx-20220822_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Aug. 22, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 22, 2022
Entity File Number 000-53862
Entity Registrant Name NUTEX HEALTH INC.
Entity Central Index Key 0001479681
Entity Tax Identification Number 11-3363609
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 6030 S. Rice Ave
Entity Address, Address Line Two Suite C
Entity Address, City or Town Houston
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77081
City Area Code 713
Local Phone Number 660-0557
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol NUTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 nutx082222form8k_htm.xml IDEA: XBRL DOCUMENT 0001479681 2022-08-22 2022-08-22 iso4217:USD shares iso4217:USD shares 0001479681 false 8-K 2022-08-22 NUTEX HEALTH INC. DE 000-53862 11-3363609 6030 S. Rice Ave Suite C Houston TX 77081 713 660-0557 false false false false Common Stock, $0.001 par value NUTX NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://nutexhealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports nutx082222form8k.htm ex99_1.htm nutx-20220822.xsd nutx-20220822_lab.xml nutx-20220822_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nutx082222form8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "nutx082222form8k.htm" ] }, "labelLink": { "local": [ "nutx-20220822_lab.xml" ] }, "presentationLink": { "local": [ "nutx-20220822_pre.xml" ] }, "schema": { "local": [ "nutx-20220822.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "NUTX", "nsuri": "http://nutexhealth.com/20220822", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "nutx082222form8k.htm", "contextRef": "From2022-08-22to2022-08-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://nutexhealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "nutx082222form8k.htm", "contextRef": "From2022-08-22to2022-08-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001607062-22-000550-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001607062-22-000550-xbrl.zip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